Synthetic oligodeoxynucleotides (ODN) containing unmethylated Cytosine-Guanine (CpG) motifs mimic the immunostimulatory activity of bacterial DNA. CpG ODN directly stimulate B cells and plasmacytoid dendritic cells (pDC), promote the production of T Helper 1 cells (Th1) and pro-inflammatory cytokines, and trigger the maturation/activation of professional antigen presenting cells.
NCI Scientists have discovered that conjugating CpG ODNs to apoptotic tumor cells to improve vaccine activity by ensuring that the ODN remains associated with the tumor antigen so that both are internalized by professional antigen presenting cells. The strategy eliminates the need to define specific tumor-associated antigens, substituting instead the entire tumor cell (which in the absence of CpG ODN is poorly immunogenic). The technology could function as an "adjuvant therapy" to eradicate metastasis when used in combination with other modalities, such as surgical removal of the primary tumor.
- Vaccines for the prevention of cancer and other indications
- Use of CpG oligonucleotides for prophylaxis and/or therapy
- Adjuvant Therapy in combination with other modalities (such as surgical removal of the primary tumor).
- Accelerates and boosts the induction of tumor-specific immunity
- Eliminates the need to define specific tumor-associated antigens, substituting instead the entire tumor cell
Dennis M. Klinman MD, PhD (NCI)
Kobayashi N, et al. [PMID 23296706]
- U.S. Patent Issued: U.S. Patent Number 8685416, Issued 01 Apr 2014